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Abstract
Background: The clinical care of people living with HIV changed fundamentally as a result of the development of
effective antiretroviral therapy (ART). HIV infection is now a long-term treatable condition. We report a national
audit to assess adherence to British HIV Association guidelines for the routine investigation and monitoring of adult
HIV-1-infected individuals.
Methods: All UK sites known as providers of adult HIV outpatient services were invited to complete a case-note
review and a brief survey of local clinic practices. Participating sites were asked to randomly select 50–100 adults,
who attended for specialist HIV care during 2014 and/or 2015. Each site collected data electronically using a self-
audit spreadsheet tool. This included demographic details (gender, ethnicity, HIV exposure, and age) and whether
22 standardised and pre-defined clinical audited outcomes had been recorded.
Results: Data were collected on 8258 adults from 123 sites, representing approximately 10% of people living with
HIV reported in public health surveillance as attending UK HIV services. Sexual health screening was provided within
96.4% of HIV services, cervical cytology and influenza vaccination within 71.4% of HIV services. There was wide
variation in resistance testing across sites. Only 44.9% of patients on ART had a documented 10-year CVD risk within
the past three years and fracture risk had been assessed within the past three years for only 16.7% patients aged
over 50 years.
Conclusions: There was high participation in the national audit and good practice was identified in some areas.
However improvements can be made in monitoring of cardiovascular risk, bone and sexual health.
Keywords: HIV, Diagnostics, Prevention
Background
In 2014, an estimated 103,700 people were living with
HIV (PLWH) in the UK, with 85,489 seen for HIV care
during the year [1, 2]. Improvements in treatments for
HIV mean that life expectancy for PLWH has increased
dramatically [3]. However with longer life expectancy we
are seeing an increasing proportion of people living with
co-morbidities including cardiovascular disease, meta-
bolic complications, and malignancy [4, 5]. As such, to
ensure optimal health outcomes for our patient cohort,
primary and secondary health promotion and disease
prevention extending beyond the virological and im-
munological control of HIV is required. The British HIV
Association (BHIVA) produces guidelines for the man-
agement of HIV infection, in the UK. The process used
by the BHIVA has been accredited by the National
Institute for Health and Clinical Excellence (NICE).
Guidelines are drafted by BHIVA Writing Groups and
then placed on the BHIVA website for consultation by
all interested parties. The BHIVA guidelines for routine
investigation and monitoring of adult HIV-1 infected
individuals 2011 recognised the paradigm shift in the
treatment of HIV infection and provided guidance on
the appropriate monitoring and assessment of adults liv-
ing with HIV [6]. These guidelines present a consensus
regarding the standard assessment and investigation of
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HIV infection from the time of diagnosis and describe
the appropriate monitoring of HIV-positive individuals
both on and off ART.
In 2015, as part of the national audit programme of the
British HIV Association (BHIVA), we audited adherence
to the BHIVA guideline on monitoring and assessment of
HIV infected individuals, and where relevant, immunisa-
tion guidelines. This article reports our findings.
Methods
All UK sites known to BHIVA as providers of adult HIV
services were invited to complete a case-note review and
a brief survey of local clinic practices. During June to
August 2015 participating sites were asked to randomly
select from the local list, 50–100 adults (aged 16 or
over), who attended for specialist HIV care during 2014
and/or 2015. The selection was random and was not
stratified. The number of cases was selected to ensure
maximum participation of sites with varying patient
populations. Data at each site were collected electronic-
ally using a self-audit spreadsheet tool. This included
demographic details (gender, ethnicity, HIV exposure,
and age) and whether audited outcomes as listed in
Table 1 had been recorded. Some of these were modified
from outcomes as specified in guidelines for ease of
assessment. To allow for varying appointment dates,
monitoring/procedures recommended as “annual” were
interpreted as within 425 days (14 months). Similarly six
monthly was taken to mean within 243 days (8 months),
except in the case of HIV viral load testing where the
guideline recommendation is to test 3–6 monthly i.e.
within six months, rather than at 6 month intervals. As
some HIV clinics do not provide influenza vaccination
or cervical cytology, information was sought as to
whether individuals had been advised to obtain these
elsewhere.
This is the first national audit of adherence to the
BHIVA monitoring and assessment guidelines. Data
were compared to the targets set in the guidelines where
applicable. Individual participating sites received their
results via the self-audit spreadsheet tool and could
compare them with national results which were pre-
sented at the BHIVA Autumn conference 2015 [7].
Statistical analysis was performed using Microsoft Excel.
Further analyses assessing the effect of adjusting for
patient mix on site-level outcomes and summarising
outcomes into meaningful groups and presenting results
as a visual dashboard have been performed and reported
elsewhere [8].
Results
Case-note review data was provided for 8258 patients
from 123 sites, but only 112 services completed the sur-
vey of clinic practices. The 8258 individuals included in
the case-note review represent approximately 10% of
PLWH reported in public health surveillance as attend-
ing UK HIV services [2]. Two thirds were male, just over
half (52.3%) acquired their HIV heterosexually, the ma-
jority were of white ethnicity (58.8%) and 60.6% were in
the 30–49 year age group (see Table 1). 62.0% (5119/
8258) of patients had been reviewed within three
months up to audit data extraction in June–August 2015
and 96.5% (7971/8258) had been reviewed within 1 year.
While it is difficult to perform a direct comparison, the
characteristics of our study population are similar to the
reported demographic data on people living with HIV in
the UK [1].
Table 2 shows the proportion of individuals achieving
the audit standards for all audited recommendations.
Baseline resistance testing
While the majority of audited cases met the national
standard for baseline resistance testing (see Table 1),
almost 1 in 5 (19.2%, n = 1586/8258) individuals did not.
However baseline resistance testing was recorded as
“not possible” for 47.3% (750/1586); 7.1% (112/1586) had
neither been tested nor had a sample stored; and for
45.4% (720/1586) it was not known whether this had
been done or the question was not answered.
Table 1 Demographics of sample
All 8258 100.0%
Sex
Male 5482 66.4%
Female 2763 33.5%
Transgendered/ transgendering 9 0.1%
Not stated 4 0.0%
Ethnicity
White 4853 58.8%
Black-African 2592 31.4%
Other 733 8.9%
Not recorded/not stated 80 1.0%
HIV Exposure
Heterosexual 4320 52.3%
MSM 3550 43.0%
IDU 153 1.9%
Other 99 1.2%
Not recorded/not stated 136 1.6%
Age
16–29 674 8.2%
30–49 5001 60.6%
50–69 2396 29.0
70+ 172 2.1%
Not stated 15 0.2%
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Table 2 Clinical monitoring standard examined and performance
Clinical Monitoring requirement audited Specified target in guidelines Proportion of cases with
documentation of meeting
audit standard % (n/N)
Whether a baseline HIV resistance test had been
done or sample stored for later testing
Patients with a genotypic resistance test performed
within 3 months of first diagnosis (or with a stored
sample available for later testing) (90%).
80.8% (6636/8258 tested,
40/8258 sample stored)
Whether HIV viral load measured within past 6 months Patients on ART with HIV viral load measured within
the last 6 months (80%).
90.1% (6660/7395)
Whether adherence assessed within past 425 days Adherence documented within the first 3 months
of starting ART (90%) and at least annually
thereafter (70%).
93.4% (6908/7395)
Whether all medication recorded within past 425 days All medication taken by patients on ART should be
reviewed annually (100%).
89.0% (6584/7395)
Whether vaccinated/immune to hepatitis A No target specified but serology recommended
followed by vaccination for all non-immune at risk
and/or co-infected with hepatitis B or C.
61.2% (5053/8258)
Whether hepatitis B serology recorded; whether anti-
surface antibody measured within past 425 days for
individuals with serology consistent with vaccination
No target specified but surface antigen (HBsAg),
anti-core total antibody (anti-HBc) and anti-
surface antibody (anti-HBs) testing recommended.
Vaccination recommended if non-immune. Annual
surface antibody titre measurement recommended
in vaccine responders.
82.1% (6781/8258)
Whether hepatitis C antibody status known No target specified but antibody testing recommended,
followed by RNA testing if antibody positive. Annual
re-testing recommended for antibody negative men who
have sex with men (MSM) or injecting drug users (IDU).
96.6% (7979/8258)
Whether CVD risk assessed, within past 3 years if
on ART, ever if not on ART
10-year cardiovascular disease (CVD) risk calculated
within 1 year of first presentation (70%), and within
the last 3 years if taking ART (70%).
44.9% (3318/7395) on ART
32.3% (279/863)
Whether smoking status recorded within past two
years; if a smoker, whether offered a cessation service.
Smoking history documented in the last 2 years
(90%) and if a smoker offered referral to a cessation
service (90%).
65.9% (5445/8258)
45.2% (862/1905) offered
cessation
Whether blood pressure recorded within past 425 days Blood pressure (BP) recorded in the last year (90%). 85.5% (7058/8258)
Whether glucose measurement recorded within past
425 days
No target specified but recommended yearly or
3–6-monthly if on ART.
77% (6359/8258)
Whether lipid profile recorded within past 425 days No target specified but recommended yearly or
6–12-monthly if on ART.
83.2% (6869/8258)
Whether liver function test (LFT) assessed within past
425 days
No target specified but recommended yearly or
3–6 monthly if on ART.
97% (8013/8258)
Whether estimated glomerular filtration rate (eGFR)
assessed within past 425 days
No target specified but recommended yearly or
3–6 monthly if on ART.
95.5% (7887/8258)
Whether urinalysis or urine protein/creatinine (uP/C)
checked within past 425 days, or 243 if receiving
tenofovir
No target specified but urinalysis and uP/C
recommended annually, with 3–6-monthly urinalysis
if receiving tenofovir.
73.7% (2050/2781)
74.8% (4098/5477) receiving
tenofovir
Whether flu vaccination had been done or record
made of advice to obtain this from general practitioner
(GP) within past year: as audit was conducted in
summer this fully covered the preceding season
No target specified in monitoring guidelines but
vaccination history recommended as part of regular
clinical review. Vaccination guidelines specify: offer
annual influenza vaccination to all HIV-infected persons
(target 95%) [14].
21.1% (1744/8258) vaccination
given
36.2% (2993/8258) advice given
Whether sexual health screen offered within
past 425 days
No target specified but recommended to offer
sexual health screen 12-monthly, or more frequently
if identified risks.
65.7% (5424/8258)
Whether syphilis serology had been done within
past 243 days
No target specified but recommended 3–6-monthly
at each routine visit for MSM and 12-monthly for others
63.0% (5201/8258)
Whether cervical cytology had been done or record
made of advice to obtain elsewhere within past
425 days, females only
No target specified but recommended 12-monthly. 53.2% (1471/2763)
Whether bone mineral density measured, individuals
aged >70 and on ART only
No target specified but recommended in all men
aged 70 years and all women aged 65 years.
17.4% (29/167)
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Antiretroviral treatment
Of 89.5% (7395/8258) audited individuals who were on
ART, 90.1% (6660/7395) had a HIV viral load measure-
ment within the past 6 months, exceeding the guideline
target of 80%, and 93.4% (6908/7395) had had ART ad-
herence assessed in the last year, which outperformed
the target of 70%. However, only 89.0% (6584/7395) had
all other medications recorded within the last year,
despite a target of 100% to avoid drug-drug interactions.
Viral hepatitis
Among audited individuals, 61.2% (5053/8258) were
hepatitis A vaccinated, immune, or seropositive, 11.9%
(n = 983/8258) were seronegative, 0.02% (2/8258)
equivocal, and for 26.9% (2220/8258) it was not known
whether this had been done or the question was not
answered.
In terms of hepatitis B, 82.1% (6781/8258) individuals
had serology fully reported (hepatitis B surface antigen
HBsAg, hepatitis B core antibody (anti-HBc) and hepatitis
B surface antibody (anti-HBs)); 0.9% (72/8258) were
HBsAg positive with incomplete antibody status; 10.2%
(841/8258) were HBsAg negative with incomplete anti-
body status; 6.8% (564/8258) had unknown HBsAg status
or the question was not answered. Among 306 chronic
hepatitis B infected (HBsAg+) individuals, 7.8% (24/306)
were apparently unvaccinated and seronegative for hepa-
titis A. Among 3605 individuals whose status was consist-
ent with vaccination (anti-HBs+, anti-HBc- and HBsAg-),
67.0% (2416) had had an annual anti-HBs measurement.
Hepatitis C antibody (anti-HCV) status was negative
for 91.3% (7539/8258) individuals, positive for 5.3%
(439/8258), equivocal for 0% (1), not known or the ques-
tion was not answered for 3.4% (279/8258). Among the
7539 seronegative individuals, 65.4% (4928) had had an
annual re-test including 74.1% (2423/3270) men who
have sex with men (MSM) and 61.8% (21/34) injecting
drug users (IDU), groups in whom this is recommended.
Hepatitis C RNA (ribonucleic acid) testing had been
done for 91.1% (400/439) anti-HCV positive patients.
Data on HCV genotyping were not collected.
Cardiovascular health
Only 44.9% (3318/7395) of patients on ART had a docu-
mented 10-year CVD risk within the past three years. Of
those not on ART, 32.3% (279/863) had 10-year CVD
risk recorded at any time, despite targets of 70% for both
groups. ART status was unclear for 18 patients. Among
1582 patients aged >50 years on ART, with no documen-
tation of established CVD, almost half (48.7%; 770) had
CVD risk calculation recorded within the last 3 years.
Smoking status had been documented within the past
two years for 65.9% (5445/8258) audited patients, well
below the target of 90%. Only 45.2% (862/1905) of
current smokers had been offered a cessation service
although this is recommended [9]. Current smokers
were not more likely to have CVD risk calculated than
ex or never smokers.
Sexual and reproductive health
An annual sexual health screen was recorded as of-
fered for 65.7% (5424/8258) of all patients, including
72.7% (2581/3550) MSM, and 60.8% (2627/4320)
heterosexuals. Syphilis serology was recorded within
the past eight months (243 days) for 63.0% (5201/
8258) of all patients, 73.4% (2604/3550) MSM, and
55.3% (2390/4320) heterosexuals.
Out of 2763 women, 53.2% (1471) had annual cervical
cytology done and 21.9% (604) had been advised to at-
tend a GP or sexual health clinic for this. The self-audit
spreadsheet tool did not provide an option for women
ineligible for cervical cytology. Contraception was
reported not relevant for 31.7% (877/2763) of women. It
had been discussed for 63.0% (1188/1886) women for
whom it was relevant.
Bone health
Fracture risk had been assessed within the past three
years for only 16.7% (430/2568) patients aged over
50 years. Bone mineral density had been measured in
17.4% (29/167) individuals aged over 70 years and re-
ceiving ART. For simplicity, the spreadsheet recorded
this from age 70 for both sexes although guidelines
recommend it from age 65 in females.
Variation in monitoring between participating sites
There was wide variation in resistance testing across
sites. 27% (33/123) sites met the target, having a re-
corded resistance test or stored sample for >90% of
audited individuals while 27% (33/123) sites achieved
Table 2 Clinical monitoring standard examined and performance (Continued)
Whether fracture risk assessed within past
3 years, individuals aged >50 only
No target specified but recommended 3-yearly
if aged over 50 years.
16.7% (430/2568)
Outcome: whether vaccinated against
pneumococcus, CD4 > 200 only
No target specified in monitoring guidelines but
vaccination history recommended as part of regular
clinical review. Vaccination guidelines recommend
pneumococcus vaccination if CD4 > 200, and
consideration of vaccination at lower CD4.
26.4% (2082/7877)
ART antiretroviral therapy
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this outcome for <75% of audited individuals, including
4.9% (6/123) sites who did so for <60%.
There was variation between sites in the proportion of
patients for whom HBsAg status was not known, and for
8 sites this exceeded 20%. There was wide variation
across sites in provision of influenza vaccination with
16/123 sites having administered or advised obtaining
influenza vaccination at their general practitioner (GP)
or Pharmacy for fewer than 10% of patients and 17/123
sites for more than 90% of patients.
There was wide variation in CVD risk calculation
between sites; of 122 sites submitting data for patients
receiving ART, 21.3% (26) met the 70% target for CVD
risk recording within three years but 27.9% (34) achieved
this for fewer than 20% of patients. There was also variation
across sites for fracture risk assessment.
Monitoring frequency
Most survey respondents routinely reviewed patients who
were stable on antiretroviral therapy every 6 months,
when HIV viral load (VL) was also checked. CD4 counts
were less frequently measured (see Table 3). Sexual health
screening was provided within 96.4% (108/123) of HIV
services, cervical cytology within 71.4%(80/123) of HIV
services and influenza vaccination within 71.4%(80/123) of
services.
Discussion
There was high participation in the national audit and
the data showed good practice in some areas. Monitor-
ing of ART was performed well; the proportions of indi-
viduals with viral load measurement and adherence
assessment exceeded the expected standard. CD4 counts
were less frequently measured in line with recent evi-
dence on CD4 count monitoring frequency [9]. The pro-
portion of individuals with all medications recorded was
high. Sexual health screening was performed well, per-
haps due to the availability of this service in the same or
adjacent clinics. Overall recording of hepatitis serology
was high but with wide variation between sites. There
was also wide variation in influenza vaccination, record-
ing of baseline resistance testing, and monitoring of
CVD risk factors and bone health. Some sites reported
very low rates of baseline resistance testing though it is
possible that this may reflect patients diagnosed and
commenced on ART before routine resistance testing
was available or recommended [10, 11].
Cardiovascular disease and smoking are major causes
of morbidity and mortality in people living with HIV [4,
12]. However, low recorded rates of monitoring of car-
diovascular health were noted and smoking status was
not reported for one in seven patients, and less than half
of current smokers were offered cessation support. The
growing population of older patients living with HIV
were also overlooked in terms of bone health, with very
low rates of fracture risk assessment and bone mineral
density recording. It is not clear if low recorded rates of
monitoring of bone density was due to a lack of avail-
ability of bone densitometry measurement.
At some sites, a significant proportion of patients had
unknown HBsAg status and many patients remain sus-
ceptible to hepatitis A, including those with documented
chronic hepatitis B infection, for whom hepatitis A could
be more serious. There was very low reported coverage
of influenza and pneumococcal vaccination, perhaps in-
dicating an issue for patients when responsibility and
funding is shared between primary and secondary care.
Limitations
Participating sites were asked to select individuals ran-
domly from those attending during 2014 and/or 2015,
but it is possible that more recent, and perhaps more
regular, attenders were over-sampled as suggested by the
fact that 62.0% of individuals had been reviewed within
three months and 96.5% within one year preceding the
audit. This may have led to over-estimation of rates of
performance and recording of routine interventions.
There was also difficulty in interpreting some targets
in the BHIVA guidelines. For example the 90% target for
baseline resistance testing (or sample storage) is applic-
able for new incident diagnoses but less clear for individ-
uals established in HIV care. As baseline resistance has
ongoing clinical relevance, it is important this informa-
tion remains accessible, including when individuals
transfer care between clinics. We considered the target
not met (80.8% individuals having recorded test or sam-
ple stored) although only 1.4% were known to be un-
tested and some of these may have started ART before
resistance testing was in use. As for all the monitoring
outcomes some findings may reflect incomplete record-
ing or reporting rather than performance.
Conclusion
Clinical services should review and develop systems to
prompt both performance and recording of recommended
interventions. Some sites have an ‘annual review’ system
Table 3 Frequency of routine monitoring for individuals
virologically stablea on ART (112 clinical services)
Clinical
review
HIV viral load
measurement
CD4 count
measurement
3 monthly 4 (3.6%) 6 (5.4%) 5 (4.5%)
4 monthly 17 (15.5%) 24 (21.4%) 16 (14.3%)
6 monthly 74 (66.1%) 78 (69.6%) 42 (37.5%)
Yearly 10 (8.9%) 1 (0.9%) 45 (40.2%)
Other or not answered 7 (6.3%) 3 (2.7%) 4 (3.6%)
avirologically stable = HIV viral load undetectable on standard assay
(<50 copies/ml)
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or electronic reminders for monitoring and, if adopted
more widely, these may improve compliance with the
monitoring guidelines. There may be a perception that
primary care is responsible for certain monitoring and
services such as cardiovascular risk and providing most
vaccinations. Hence greater clarity from commissioners
about where responsibility lies in these areas, particu-
larly in what the forthcoming tariffs for HIV care cover,
will help HIV services focus on areas they are respon-
sible for. Improved communication between HIV and
primary care services would streamline and improve
care for people living with HIV. Clinical services should
also develop improved strategies to care for older
patients living with HIV [13].
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